• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by InfuSystems Holdings Inc.

    2/13/24 5:06:24 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care
    Get the next $INFU alert in real time by email
    SC 13G 1 tv01181-infusystemholdingsin.htm SCHEDULE 13G infusystemholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  InfuSystem Holdings Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  45685K102

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  45685K102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    29,647

    7.  SOLE DISPOSITIVE POWER

    1,027,775

    8.  SHARED DISPOSITIVE POWER

    37,523

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,065,298

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.03%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    InfuSystem Holdings Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3851 West Hamlin Road
    Rochester Hills, MI 48309

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    45685K102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $INFU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INFU

    DatePrice TargetRatingAnalyst
    7/22/2025$12.00Buy
    Roth Capital
    9/26/2024$13.00Buy
    B. Riley Securities
    More analyst ratings

    $INFU
    SEC Filings

    View All

    SEC Form 10-Q filed by InfuSystems Holdings Inc.

    10-Q - InfuSystem Holdings, Inc (0001337013) (Filer)

    8/5/25 5:17:03 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystems Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

    8/5/25 6:29:43 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InfuSystem Holdings, Inc (0001337013) (Filer)

    7/29/25 4:28:01 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Eichenbaum Kenneth D. bought $10,360 worth of shares (2,000 units at $5.18), increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/28/25 4:24:49 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Director Hundzinski Ronald T bought $30,450 worth of shares (5,000 units at $6.09) (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/20/25 6:54:45 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    President and COO Lachance Carrie bought $18,987 worth of shares (3,132 units at $6.06), increasing direct ownership by 2% to 190,212 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/19/25 7:58:16 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InfuSystem Reports Second Quarter 2025 Financial Results

    Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0

    8/5/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

    Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the

    7/29/25 4:30:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Reports First Quarter 2025 Financial Results

    Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

    5/8/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on InfuSystem with a new price target

    Roth Capital initiated coverage of InfuSystem with a rating of Buy and set a new price target of $12.00

    7/22/25 7:53:05 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on InfuSystem with a new price target

    B. Riley Securities initiated coverage of InfuSystem with a rating of Buy and set a new price target of $13.00

    9/26/24 7:35:18 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Northland Capital initiated coverage on InfuSystem with a new price target

    Northland Capital initiated coverage of InfuSystem with a rating of Outperform and set a new price target of $27.00

    4/26/21 8:42:07 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shuda Scott disposed of 2,242 shares and sold $55,622 worth of shares (5,752 units at $9.67), decreasing direct ownership by 8% to 94,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    8/22/25 5:33:54 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    New insider Sviokla John J claimed ownership of 10,000 shares (SEC Form 3)

    3 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    6/16/25 7:38:02 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Director Eichenbaum Kenneth D. bought $10,360 worth of shares (2,000 units at $5.18), increasing direct ownership by 50% to 6,000 units (SEC Form 4)

    4 - InfuSystem Holdings, Inc (0001337013) (Issuer)

    5/28/25 4:24:49 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Leadership Updates

    Live Leadership Updates

    View All

    InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

    The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping down as the Company's Chief Executive Officer, effective May 19, 2025. Concurrently, the Company announced that Carrie Lachance, the Company's President and Chief Operating Officer, and a member of the Company's board of directors, will assume the role of Chief Executive Officer effective May 19

    4/1/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Appoints Ronald Hundzinski to the Board of Directors

    InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of Ronald Hundzinski, as an independent director to InfuSystem's Board of Directors, effective November 12, 2024. Mr. Hundzinski will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2025. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Ron to InfuSystem's Board. He adds both accounting and finance depth to our oversight and committee work and

    11/18/24 9:15:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

    InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem's Board of Directors, effective September 20, 2022. Mr. Malhotra will serve as a director until he stands for election at InfuSystem's next Annual Shareholders meeting in May 2023. Scott Shuda, Chairman of InfuSystem's Board of Directors, said, "We are pleased to welcome Rimmy as a new independent director on InfuSystem's Board. Rimmy first invested in the Company in 2012, and has

    9/23/22 4:05:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Financials

    Live finance-specific insights

    View All

    InfuSystem Reports Second Quarter 2025 Financial Results

    Record Net Revenues of $36.0 million Representing 7% Growth from the Prior Year Net income of $2.6 million, up 262% Adjusted EBITDA (non-GAAP) of $8.0 million, up 32% Adjusted EBITDA (non-GAAP) margin expanded by 4.3% to 22.3% Year-to-Date Net Operating Cash Flow of $8.8 million, up 227% Stock Repurchases totaled $3.5 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Overview: Net revenues totaled $36.0

    8/5/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem to Report Second Quarter 2025 Financial Results on August 5, 2025

    Investor Conference Call to be held 9:00 a.m. Eastern Time InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The Company will also conduct a conference call for all interested parties on Tuesday, August 5, 2025 at 9:00 a.m. Eastern Time to discuss its financial results. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the

    7/29/25 4:30:00 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    InfuSystem Reports First Quarter 2025 Financial Results

    Record Net Revenues of $34.7 million Representing 9% Growth from the Prior Year Net loss of $0.3 million Adjusted EBITDA (non-GAAP) of $6.3 million, up 64% Adjusted EBITDA (non-GAAP) margin expanded by 6.2% to 18.2% Stock Repurchases totaled approximately $3.0 million InfuSystem Holdings, Inc. (NYSE:INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2025. 2025 First Quarter Overview: Net revenues totaled $34.7 million, an increase of 9% vs. prior year. Patient Services net rev

    5/8/25 6:30:00 AM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    $INFU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    12/9/24 6:38:13 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    12/6/24 5:07:04 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by InfuSystems Holdings Inc.

    SC 13D/A - InfuSystem Holdings, Inc (0001337013) (Subject)

    9/24/24 2:06:02 PM ET
    $INFU
    Medical/Dental Instruments
    Health Care